Oncology Central

Emerging immunotherapy and strategies directly targeting B cells for the treatment of diffuse large B-cell lymphoma

0

During the last decade, significant prolonged survival in diffusive large B-cell lymphoma (DLBCL) has been observed. The efficacy of initial treatment improved mostly due to addition of a chimeric anti-CD20 monoclonal antibody (rituximab) to standard chemotherapeutic regimens. Moreover, accurate understanding of DLBCL pathogenesis and remarkable progress in gene expression profiling have led to the development of a variety of tumor-specific regimens.

To view restricted content, please:
Share:

Leave A Comment